New Technology and Gene Therapy Workshop wrapup

First WFH-led New Technology and Gene Therapy Workshop held in Montreal

The 18th WFH New Technology and Gene Therapy Workshop—led by the WFH for the first time—was held in Montreal, Canada, on November 7 and 8, 2024. This small, high-level scientific meeting brought together approximately 70 experts from diverse fields—including immunologists, clinicians, researchers, and patients—to explore new frontiers in hemophilia treatment. The workshop provided an opportunity for experts in the field to share their latest findings, collaborate on innovative approaches, and discuss the challenges facing novel technologies for hemophilia, including but not limited to, gene therapy.

Also available in: Français Español

The New Technology and Gene Therapy Workshop has been held every few years since 1996 and was most recently hosted by the National Bleeding Disorders Foundation (NBDF). Building upon this history, the WFH organized the 18th edition, continuing a long tradition of advancing care for people with hemophilia through cutting-edge research.

Day one of the workshop focused on immunological issues and toxicities associated with gene transfer; monoclonal and bispecific antibodies for hemophilia and other coagulation disorders; and non-viral gene therapy/gene editing.

Presentations on day two covered the need for improved FVIII transgenes or alternatives; other vector systems and innovative clinical trials; and the latest updates on AAV vectors. A patient panel discussed the state of the science.

The 18th New Technology and Gene Therapy Workshop provided a unique opportunity for participants to come together, emphasizing the community’s commitment to advancing new technologies and ensuring that innovative treatments can benefit all patients

The 18th WFH New Technology and Gene Therapy Workshop was supported by:
Visionary partners: CSL Behring and Spark Therapeutics
Leading partner: Pfizer
Collaborating partner: Biomarin
With additional thanks to: HC Bioscience, Hemab, Metagenomi, NBDF, STAR therapeutics

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.